Wanbury Valuation

Is WANBURY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

Below Fair Value
Significantly Below Fair Value
Price-To-Earnings vs Peers
Price-To-Earnings vs Industry
Price-To-Earnings vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of WANBURY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate WANBURY's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate WANBURY's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for WANBURY?

Key metric: As WANBURY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for WANBURY. This is calculated by dividing WANBURY's market cap by their current earnings.
What is WANBURY's PE Ratio?
PE Ratio	14.4x
Earnings	₹523.05m
Market Cap	₹7.54b

WANBURY key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	1.5x
Enterprise Value/EBITDA	12.6x
PEG Ratio	n/a

Price to Earnings Ratio vs Peers

How does WANBURY's PE Ratio compare to its peers?

The above table shows the PE ratio for WANBURY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PE	Estimated Growth	Market Cap
Peer Average	48.9x
524075 Albert David	11.1x	n/a	₹7.6b
NECLIFE Nectar Lifesciences	128.7x	n/a	₹7.9b
SAKAR Sakar Healthcare	54x	n/a	₹6.7b
INDSWFTLAB Ind-Swift Laboratories	1.7x	n/a	₹6.3b
WANBURY Wanbury	14.4x	n/a	₹7.5b

Price-To-Earnings vs Peers: WANBURY is good value based on its Price-To-Earnings Ratio (14.4x) compared to the peer average (48.9x).

Price to Earnings Ratio vs Industry

How does WANBURY's PE Ratio compare vs other companies in the IN Pharmaceuticals Industry?

2 Companies	Price / Earnings	Estimated Growth	Market Cap
INDSWFTLAB Ind-Swift Laboratories	1.7x	n/a	US$74.22m
524652 Ind-Swift	2.8x	n/a	US$13.24m

No more companies available in this PE range

2 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Earnings vs Industry: WANBURY is good value based on its Price-To-Earnings Ratio (14.4x) compared to the Indian Pharmaceuticals industry average (32.7x).

Price to Earnings Ratio vs Fair Ratio

What is WANBURY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

WANBURY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio	14.4x
Fair PE Ratio	n/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate WANBURY's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

IOL Chemicals and Pharmaceuticals

₹21.8b

Manufactures and sells pharmaceutical and chemical products in India and internationally.

IOLCP

₹371.55

-6.7%

-12.4%

Mercury Laboratories

₹1.1b

Develops, manufactures, markets, distributes, and sells pharmaceutical drugs, medicines, and formulations for mother and child healthcare in India and internationally.

538964

₹944.45

-3.5%

18.1%

Solara Active Pharma Sciences

₹36.4b

Manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally.

SOLARAPP

₹468.50

-5.7%

n/a